Under the terms of the agreement, Illumina will use Sentrix Arrays in conjunction with the company’s GoldenGate and Infinium assays to conduct genetic studies for thousands of samples provided by GSK.
Illumina’s genotyping technologies enable researchers to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics.
This information may help the researchers to create personalized medicine by correlating genetic variation and gene function with particular disease states, enhancing drug discovery, allowing diseases to be detected earlier and more specifically, and permitting better choices of drugs for individual patients.
Illumina has worked directly with GSK since June 2001, genotyping samples for a number of pharmacogenomics studies.